Skip to content
Peptide research

S14G-HN (Humanin Analog)

Also known as Humanin-G · HNG
Category
Longevity & Anti-Aging
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

S14G-HN is a superpotent synthetic analog of humanin, marketed for neuroprotection, cardiac and kidney protection, and general anti-aging cytoprotection. The case rests almost entirely on animal and cell studies; human evidence is low or speculative, with no established human safety profile. Its anti-apoptotic mechanism also raises an unresolved theoretical cancer concern. Not an approved drug in the US, and supply is unregulated research-grade material.

Read Full record

Studied uses & evidence

Studied uses(9)

  • Neuroprotection against Alzheimer's disease pathology

    Low

    Multiple rodent studies show cognitive benefit, no human trials, and two related papers were retracted.

  • Cardioprotection and reduction of ischemia/reperfusion injury

    Low

    Reduced infarct size in mice and pigs, but benefit disappeared with longer ischemia; no human trials.

  • Anti-inflammatory effects across multiple tissues

    Low

    Reduced inflammation in small rodent and cell studies across several tissues; no human data yet.

Evidence limits

Evidence Level
Preclinical

All efficacy data for S14G-HN comes from cell culture and animal (primarily mouse and rat) models, with one large-animal study in pigs (Sharp et al. 2020). Human data is limited to observational and correlational studies measuring endogenous humanin levels as biomarkers in aging, Alzheimer's disease, AMD, gestational diabetes, and metabolic disease — none involving administration of exogenous S14G-HN. Endogenous humanin levels decline with age, are elevated in centenarian offspring (Barzilai/Cohen labs), are approximately 37% lower in AMD patients than age-matched controls, and correlate positively with ovarian reserve in follicular fluid. The preclinical evidence is robust and consistent across neuroprotection, cardioprotection, metabolic regulation, retinal protection, renal protection, and anti-inflammatory applications spanning multiple independent laboratories worldwide. However, the complete absence of human interventional data means no clinical efficacy or safety profile has been established.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Active cancer

    Moderate

    More potent humanin analog with enhanced anti-apoptotic activity. May protect tumor cells from apoptosis.

  • Diabetes/insulin therapy (hypoglycemia risk)

    Moderate

    Humanin analogs improve insulin sensitivity and glucose-stimulated insulin secretion. May potentiate hypoglycemia with insulin therapy.

General cautions

  • Pregnancy

    Absolute

    No human safety data. Potent anti-apoptotic signaling via STAT3 pathway.

Risk summary(8)

Risks = level of concern: High · Moderate · Low · Theoretical

  • No established human safety profile

    High
  • Potential cancer promotion via anti-apoptotic effects

    Moderate
  • Research-grade product quality and purity concerns

    High
  • Modulation of IGF-1/IGFBP-3 axis

    Moderate
  • Additive bleeding risk due to antiplatelet effects

    Moderate
  • Short and poorly characterized plasma half-life

    Moderate
  • Injection site reactions

    Low
  • Unknown effects on immune surveillance and inflammation

    Theoretical
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.